T CELL MEMORY

T细胞记忆

基本信息

  • 批准号:
    7958181
  • 负责人:
  • 金额:
    $ 5.67万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-05-01 至 2010-04-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Following infection with viruses such as HIV, antigens select specific lymphocytes from a large repertoire of T and B cells and induce them to selectively proliferate. These activated lymphocytes facilitate rapid antigen clearance and, upon neutralization of the pathogenic threat, they persist in the host as memory lymphocytes for a lifetime. The phenomenon of "original antigenic sin", first described in humans vaccinated against influenza virus, stands out as a paradox to Burnet's rules of B cell engagement. Humans previously exposed to influenza virus, upon infection with a novel influenza strain, produce antibodies directed primarily against the older viral strains at the expense of responses to novel protective antigenic determinants thus exacerbating the severity of the current infection. This blind spot of the immune system and the redirection of responses to the "original antigen," but not to novel epitopes in the current virus is a phenomenon which recent reports have questioned. Hence, we revisited this issue to determine the extent to which OAS is induced by variant influenza viruses. Using two related strains of influenza A viruses, we have shown that OAS can lead to a significant decrease in the development of immune memory and recall responses. In addition, we have shown that sequential infection of mice with live influenza virus strains leads to almost exclusive neutralizing antibody responses to the first viral strain suggesting that the induction of OAS could be a potential strategy by which variant influenza viruses subvert the immune system.
这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者(PI)可能从另一个NIH来源获得了主要资金, 因此可以在其他CRISP条目中表示。所列机构为 研究中心,而研究中心不一定是研究者所在的机构。 在感染HIV等病毒后,抗原从大量T和B细胞中选择特异性淋巴细胞,并诱导它们选择性增殖。这些活化的淋巴细胞促进快速抗原清除,并且在中和病原威胁后,它们作为记忆淋巴细胞在宿主中持续存在一生。最初在接种流感病毒疫苗的人类中描述的“原始抗原罪”现象,作为伯内特的B细胞接合规则的悖论而突出。先前接触过流感病毒的人类,在感染新型流感病毒株后,会产生主要针对旧病毒株的抗体,但代价是对新型保护性抗原决定簇的反应,从而加剧了当前感染的严重程度。这种免疫系统的盲点和对“原始抗原”的反应的重定向,而不是对当前病毒中的新表位的反应,是最近报道质疑的现象。因此,我们重新审视了这个问题,以确定变异流感病毒诱导OAS的程度。 使用两种相关的甲型流感病毒株,我们已经表明OAS可以导致免疫记忆和回忆反应的发展显着下降。 此外,我们已经表明,用活流感病毒株连续感染小鼠导致对第一种病毒株的几乎排他性的中和抗体应答,这表明OAS的诱导可能是变异流感病毒破坏免疫系统的潜在策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOSHY JACOB其他文献

JOSHY JACOB的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOSHY JACOB', 18)}}的其他基金

Somatic hypermutation and rescue from self-reactivity in Pre-B lymphocytes
Pre-B 淋巴细胞的体细胞超突变和自身反应的拯救
  • 批准号:
    10153689
  • 财政年份:
    2020
  • 资助金额:
    $ 5.67万
  • 项目类别:
Overcoming maternal antibody-mediated immunosuppression
克服母源抗体介导的免疫抑制
  • 批准号:
    8534701
  • 财政年份:
    2012
  • 资助金额:
    $ 5.67万
  • 项目类别:
Overcoming maternal antibody-mediated immunosuppression
克服母源抗体介导的免疫抑制
  • 批准号:
    8704872
  • 财政年份:
    2012
  • 资助金额:
    $ 5.67万
  • 项目类别:
Overcoming maternal antibody-mediated immunosuppression
克服母源抗体介导的免疫抑制
  • 批准号:
    8899425
  • 财政年份:
    2012
  • 资助金额:
    $ 5.67万
  • 项目类别:
Negative regulation of Plasma cells by CD28 and B7 molecules
CD28 和 B7 分子对浆细胞的负调控
  • 批准号:
    8513589
  • 财政年份:
    2012
  • 资助金额:
    $ 5.67万
  • 项目类别:
Overcoming maternal antibody-mediated immunosuppression
克服母源抗体介导的免疫抑制
  • 批准号:
    9114473
  • 财政年份:
    2012
  • 资助金额:
    $ 5.67万
  • 项目类别:
Overcoming maternal antibody-mediated immunosuppression
克服母源抗体介导的免疫抑制
  • 批准号:
    8299339
  • 财政年份:
    2012
  • 资助金额:
    $ 5.67万
  • 项目类别:
B CELL MEMORY AND ORIGINAL ANTIGENIC SIN
B 细胞记忆和原罪抗原
  • 批准号:
    8357483
  • 财政年份:
    2011
  • 资助金额:
    $ 5.67万
  • 项目类别:
B CELL MEMORY
B细胞记忆
  • 批准号:
    8172441
  • 财政年份:
    2010
  • 资助金额:
    $ 5.67万
  • 项目类别:
B CELL MEMORY
B细胞记忆
  • 批准号:
    7958268
  • 财政年份:
    2009
  • 资助金额:
    $ 5.67万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 5.67万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 5.67万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 5.67万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5.67万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 5.67万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 5.67万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 5.67万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 5.67万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 5.67万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 5.67万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了